Hao Y, Liu W, Liu Y, Liu Y, Xu Z, Ye Y, Zhou H, Deng H, Zuo H, Yang H, Li Y
Authors not listed · 2023
This COVID-19 drug study was incorrectly included in EMF research databases, highlighting data quality issues.
Plain English Summary
This study appears to be incorrectly categorized in an EMF database, as it actually examined Paxlovid (a COVID-19 antiviral medication) in hospitalized patients, not electromagnetic field exposure. The research found that Paxlovid did not significantly reduce mortality or speed viral clearance in hospitalized COVID-19 patients with severe health conditions. This pharmaceutical study has no relevance to EMF health effects research.
Why This Matters
This study highlights a critical issue in EMF research databases: proper categorization and relevance screening. When pharmaceutical studies like this Paxlovid trial get mixed into EMF research collections, it creates confusion and undermines the credibility of legitimate EMF health research. The science demonstrates that accurate data curation is essential for understanding real EMF health effects. What this means for you is that when researching EMF health impacts, you need to verify that studies actually examined electromagnetic field exposure, not unrelated medical interventions. The reality is that misclassified studies dilute the quality of EMF research databases and can lead to incorrect conclusions about wireless technology health effects.
Exposure Information
Specific exposure levels were not quantified in this study.
Show BibTeX
@article{hao_y_liu_w_liu_y_liu_y_xu_z_ye_y_zhou_h_deng_h_zuo_h_yang_h_li_y_ce3258,
author = {Unknown},
title = {Hao Y, Liu W, Liu Y, Liu Y, Xu Z, Ye Y, Zhou H, Deng H, Zuo H, Yang H, Li Y},
year = {2023},
doi = {10.1016/j.lanwpc.2023.100694},
}